Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC

University of California, Department of Neurology, Brain Tumor Research Center and Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA.
Cancer cell (Impact Factor: 23.52). 05/2012; 21(5):601-13. DOI: 10.1016/j.ccr.2012.04.012
Source: PubMed


The proto-oncogene MYCN is mis-expressed in various types of human brain tumors. To clarify how developmental and regional differences influence transformation, we transduced wild-type or mutationally stabilized murine N-myc(T58A) into neural stem cells (NSCs) from perinatal murine cerebellum, brain stem, and forebrain. Transplantation of N-myc(WT) NSCs was insufficient for tumor formation. N-myc(T58A) cerebellar and brain stem NSCs generated medulloblastoma/primitive neuroectodermal tumors, whereas forebrain NSCs developed diffuse glioma. Expression analyses distinguished tumors generated from these different regions, with tumors from embryonic versus postnatal cerebellar NSCs demonstrating Sonic Hedgehog (SHH) dependence and SHH independence, respectively. These differences were regulated in part by the transcription factor SOX9, activated in the SHH subclass of human medulloblastoma. Our results demonstrate context-dependent transformation of NSCs in response to a common oncogenic signal.

Download full-text


Available from: Matt Grimmer,
  • Source
    • "The G34V mutation was linked to an altered transcriptional status of the cells, with quite widespread changes in RNA polymerase II association and levels of K36 methylation when compared with a glioma cell line wild-type for H3.3. One locus that was particularly induced was MYCN, an oncogene implicated in pediatric glioblastoma (Swartling et al. 2012). Transduction of G34V mutant H3.3 into normal human astrocytes or into transformed human fetal glial cells was sufficient to induce N- MYC expression two-to threefold over cells transduced with WT H3.3 (Bjerke et al. 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Brain tumors are the most common solid tumors in children. Pediatric high-grade glioma (HGG) accounts for ∼8-12 % of these brain tumors and is a devastating disease as 70-90 % of patients die within 2 years of diagnosis. The failure to advance therapy for these children over the last 30 years is largely due to limited knowledge of the molecular basis for these tumors and a lack of disease models. Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78 % of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36 % of non-brainstem gliomas carrying either K27M or G34R/V mutations. Although mutations in many chromatin modifiers have been identified in cancer, this was the first demonstration that histone mutations may be drivers of disease. Subsequent studies have identified high-frequency mutation of histone H3 to K36M in chondroblastomas and to G34W/L in giant cell tumors of bone, which are diseases of adolescents and young adults. Interestingly, the G34 mutations, the K36M mutations, and the majority of K27M mutations occur in genes encoding the replacement histone H3.3. Here, we review the peculiar characteristics of histone H3.3 and use this information as a backdrop to highlight current thinking about how the identified mutations may contribute to disease development.
    Chromosoma 03/2015; 124(2). DOI:10.1007/s00412-015-0510-4 · 4.60 Impact Factor
  • Source
    • "The inhibition of its activity mediates the impaired cell cycle progression and reduced cell invasion induced by miR-145 tumor suppressor [101]. In contrast, ectopic expression of SOX9 cooperates to transform NSCs and form tumors with a primitive neuroectodermal tumor profile [40], establishing his functional relevance in the regulation of GSCs (Figure 1). Beyond the CNS tumors, Sox9 interacts with pathways and genes also altered in GBM such as EGFR, BMI-1 and PTEN [102] [103] [104] [105] and these connections might be interesting to be further investigated in GBM. "
    [Show abstract] [Hide abstract]
    ABSTRACT: SOX genes are developmental regulators with functions in the instruction of cell fate and maintenance of progenitor's identity during embryogenesis. They play additional roles during tissue homeostasis and regeneration in adults particularly in the Central Nervous System (CNS). In the last years a growing number of evidences has shown that mutations and dysfunction of SOX factors are implicated in several human diseases, including a variety of cancers. In this review, we will summarize the current knowledge about SOX family in CNS tumors and their role in the origin and maintenance of the subpopulation of cancer stem cells in these tumors.
    American Journal of Cancer Research 07/2014; 4(4):312-24. · 4.17 Impact Factor
  • Source
    • "There is no specific preclinical mouse model that fully recapitulates the human group 4 medulloblastoma, although one has been described that expresses MycN and luciferase under the control of a brain-specific promoter and develops either SHH or non-SHH medulloblastoma depending on the time of tumor initiation.55 It is unclear if this non-SHH medulloblastoma mouse model is an accurate representation of conventional group 4 tumors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Medulloblastoma is the commonest malignant brain tumor in children. Treatment with surgery, irradiation, and chemotherapy has improved outcomes in recent years, but patients are frequently left with devastating neurocognitive and other sequelae following such therapy. While the prognosis has traditionally been based on conventional histopathology and clinical staging (based on age, extent of resection, and presence or absence of metastasis), it has become apparent in recent years that the inherent biology of the tumor plays a significant part in predicting survival and sometimes supersedes clinical or pathologic risk factors. The advent of deep sequencing gene technology has provided invaluable clues to the molecular makeup of this tumor and allowed neuro-oncologists to understand that medulloblastoma is an amalgamation of several distinct disease entities with unique clinical associations and behavior. This review is a concise summary of the pathology, genetic syndromes, recent advances in molecular subgrouping, and the associated gene mutations and copy number variations in medulloblastoma. The association of molecular alterations with patient prognosis is also discussed, but it should be remembered that further validation is required in prospective clinical trials utilizing uniform treatment approaches.
    Pharmacogenomics and Personalized Medicine 02/2014; 7(1):43-51. DOI:10.2147/PGPM.S38698
Show more